Introduction

The U.S. Government Accountability Office (GAO), the evaluation arm of Congress, is studying the use
of performance information at FDA as part of a Congressional request. As part of this study, we are
surveying a random sample of mid- and upper-level federal employees at FDA. This survey is
designed to obtain information on your experiences and perceptions with regard to performance management
and related challenges.

This survey is based on similar surveys that we administered in 1996, 1999, 2003, and 2007. Most of the
questions in this survey can be answered by checking boxes or filling in blanks. The survey
should take no more than 20-25 minutes to complete.

We urge you to complete this survey. We cannot develop meaningful information without your frank
and honest answers.

To learn more about completing the survey, printing your responses,
and who to contact if you have questions, _____.

Thank you in advance for your assistance in taking part in our survey.

Survey of Performance and Management at the Food and Drug Administration (FDA)

U.S. Government Accountability Office

QuestionChoices

EstimatedPercentage

95 PercentConfidence Interval

1--All FDA Managers

Very great extent

24.1

19.5-28.7

Great extent

37.4

32.2-42.6

Moderate extent

22.4

17.9-26.9

Small extent

7.0

4.6-10.1

No extent

2.2

0.8-4.7

No basis to judge/Not applicable

6.6

4.1-10.0

No answer

0.3

0.0-1.6

2--CDER/CBER/CDRH Managers

Very great extent

21.1

14.2-29.5

Great extent

37.2

28.6-45.8

Moderate extent

24.2

16.8-32.8

Small extent

7.2

3.3-13.3

No extent

2.4

0.4-7.4

No basis to judge/Not applicable

7.9

3.9-13.9

No answer

0.0

0.0-2.9

3--CFSAN Managers

Very great extent

13.4

7.7-21.1

Great extent

47.2

38.0-56.4

Moderate extent

24.4

16.9-33.4

Small extent

11.7

6.4-19.1

No extent

1.7

0.2-6.1

No basis to judge/Not applicable

1.7

0.2-6.1

No answer

0.0

0.0-4.8

4--ORA Managers

Very great extent

24.5

17.1-33.2

Great extent

37.2

28.5-45.9

Moderate extent

22.0

15.0-30.5

Small extent

7.6

3.5-14.0

No extent

1.1

0.1-5.0

No basis to judge/Not applicable

6.5

2.8-12.6

No answer

1.1

0.1-5.0

7. For those program(s)/operation(s)/project(s) that you are involved with, to what extent,
if at all, do you consider goals from the following FDA plans or initiatives when making management
decisions such as setting priorities or allocating resources?

(Note: In accord with the instructions provided for responding to Question 8, please note that the"No Answer" category for this question includes respondents who did not answer "Yes" onQuestion 8.)

The SAS System

Survey of Performance and Management at the Food and Drug Administration (FDA)

U.S. Government Accountability Office

QuestionChoices

EstimatedPercentage

95 PercentConfidence Interval

1--All FDA Managers

Very great extent

4.6

2.5-7.5

Great extent

9.6

6.7-13.3

Moderate extent

16.1

12.4-20.4

Small extent

17.2

13.4-21.1

No extent

12.8

9.6-16.5

No basis to judge/Not applicable

12.8

9.3-16.9

No answer

26.9

22.2-31.7

2--CDER/CBER/CDRH Managers

Very great extent

3.1

0.8-8.2

Great extent

3.4

1.1-8.0

Moderate extent

15.6

9.8-23.2

Small extent

15.7

9.8-23.5

No extent

16.7

10.5-24.6

No basis to judge/Not applicable

15.4

9.4-23.2

No answer

30.0

21.8-38.2

3--CFSAN Managers

Very great extent

3.3

0.9-8.6

Great extent

6.7

2.8-13.0

Moderate extent

14.4

8.6-22.1

Small extent

27.8

19.5-36.0

No extent

18.4

11.7-26.8

No basis to judge/Not applicable

10.0

5.1-17.1

No answer

19.4

12.6-27.9

4--ORA Managers

Very great extent

2.2

0.4-6.7

Great extent

16.3

10.1-24.2

Moderate extent

16.6

10.4-24.5

Small extent

18.8

12.2-26.9

No extent

13.3

7.8-20.7

No basis to judge/Not applicable

13.0

7.5-20.5

No answer

19.8

13.1-28.1

Performance Measurement (Continued)

10. For those program(s)/operation(s)/project(s) that you are involved with, to what extent,
if at all, do you use the information obtained from performance measurement when participating
in the following activities?

Survey of Performance and Management at the Food and Drug Administration (FDA)

U.S. Government Accountability Office

data intentionally not reported

12. Over the past several years, for those program(s)/operation(s)/project(s) that you are involved
with, has managers' use of performance information at FDA increased, decreased or remained about the same?

(Note: In accord with the instructions provided for responding to Question 8, please note that the"No Answer" category for this question includes respondents who did not answer "Yes" onQuestion 8.)

The SAS System

Survey of Performance and Management at the Food and Drug Administration (FDA)

U.S. Government Accountability Office

QuestionChoices

EstimatedPercentage

95 PercentConfidence Interval

1--All FDA Managers

Increased greatly

16.4

12.5-21.0

Increased somewhat

27.3

22.7-31.9

Stayed about the same

21.4

17.0-25.8

Decreased somewhat

0.9

0.2-2.3

Decreased greatly

0.2

0.0-0.6

No basis to judge

6.7

4.4-9.8

No answer

27.1

22.3-31.9

2--CDER/CBER/CDRH Managers

Increased greatly

13.1

7.6-20.6

Increased somewhat

25.9

18.5-34.5

Stayed about the same

23.2

15.9-31.9

Decreased somewhat

0.0

0.0-2.9

Decreased greatly

0.0

0.0-2.9

No basis to judge

7.7

3.8-13.5

No answer

30.0

21.8-38.2

3--CFSAN Managers

Increased greatly

3.3

0.9-8.6

Increased somewhat

35.5

26.8-44.2

Stayed about the same

28.4

20.1-36.7

Decreased somewhat

1.7

0.2-6.1

Decreased greatly

1.7

0.2-6.1

No basis to judge

8.3

4.0-15.1

No answer

21.1

14.0-29.7

4--ORA Managers

Increased greatly

22.0

15.0-30.5

Increased somewhat

28.8

20.7-37.0

Stayed about the same

20.6

13.7-29.0

Decreased somewhat

2.2

0.4-6.7

Decreased greatly

0.0

0.0-3.1

No basis to judge

6.5

2.8-12.6

No answer

19.8

13.1-28.1

Performance Measurement (Continued)

13. Based on your experience with the program(s)/operation(s)/project(s) that you are involved with,
to what extent, if at all, have the following factors hindered measuring performance
or using the performance information?

Survey of Performance and Management at the Food and Drug Administration (FDA)

U.S. Government Accountability Office

QuestionChoices

EstimatedPercentage

95 PercentConfidence Interval

1--All FDA Managers

Yes

35.7

30.5-40.9

No

44.7

39.4-49.9

Not sure

18.8

14.7-22.9

Not checked

0.8

0.2-2.2

2--CDER/CBER/CDRH Managers

Yes

41.7

33.0-50.4

No

34.7

26.4-43.0

Not sure

23.3

16.1-31.8

Not checked

0.3

0.1-0.9

3--CFSAN Managers

Yes

23.4

15.9-32.3

No

58.3

49.2-67.3

Not sure

18.4

11.7-26.8

Not checked

0.0

0.0-4.8

4--ORA Managers

Yes

28.5

20.4-36.6

No

51.9

43.0-60.9

Not sure

17.4

11.0-25.4

Not checked

2.2

0.4-6.7

Management Challenges

18. Based on your experience with the program(s)/operation(s)/project(s) that you are involved with,
to what extent, if at all, do you believe that FDA is making progress addressing each of the following
management challenges?(Select one answer in each row.)

Survey of Performance and Management at the Food and Drug Administration (FDA)

U.S. Government Accountability Office

QuestionChoices

EstimatedPercentage

95 PercentConfidence Interval

1--All FDA Managers

Very great extent

5.6

3.6-8.2

Great extent

19.3

15.3-23.3

Moderate extent

17.7

14.1-21.4

Small extent

10.1

7.2-13.6

No extent

2.2

1.0-4.1

No basis to judge/Not applicable

44.4

40.0-48.8

No answer

0.7

0.1-2.3

2--CDER/CBER/CDRH Managers

Very great extent

2.2

0.3-7.0

Great extent

3.1

0.8-8.2

Moderate extent

5.4

2.3-10.7

Small extent

5.1

1.9-10.8

No extent

2.2

0.3-7.0

No basis to judge/Not applicable

80.9

72.8-87.6

No answer

1.0

0.1-4.8

3--CFSAN Managers

Very great extent

8.3

4.0-15.1

Great extent

31.7

23.2-40.3

Moderate extent

24.4

16.9-33.4

Small extent

22.1

15.0-30.7

No extent

6.7

2.8-13.0

No basis to judge/Not applicable

6.7

2.8-13.0

No answer

0.0

0.0-4.8

4--ORA Managers

Very great extent

12.2

7.0-19.5

Great extent

31.0

22.7-39.3

Moderate extent

26.0

18.4-34.9

Small extent

14.1

8.4-21.7

No extent

2.2

0.4-6.7

No basis to judge/Not applicable

13.3

7.8-20.7

No answer

1.1

0.1-5.0

Management Challenges - An Example

19. Please provide an example of how FDA has made progress or not made progress to address any of the management
challenges listed in question 18 above.(In your answer, please indicate which challenge from question 18 your example applies to.)